Please try another search
MyMD Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 4 million compared to USD 15.2 million a year ago. Basic loss per share from continuing operations was USD 5.33 compared to USD 11.74 a year ago. Diluted loss per share from continuing operations was USD 5.33 compared to USD 11.74 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -4.91 | -3.84 | -5.78 | -1.83 |
Net Income | -2.36 | 4.04 | -4.17 | -1.51 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 17.86 | 21.83 | 25.25 | 28.41 |
Total Liabilities | 5.09 | 5.72 | 13.75 | 14.4 |
Total Equity | 12.77 | 16.11 | 11.5 | 14.01 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1.93 | -3.16 | -3.92 | -3.97 |
Cash From Investing Activities | 5.93 | 3.36 | 3.83 | -11.27 |
Cash From Financing Activities | -1.62 | 0 | 0 | 14.69 |
Net Change in Cash | 2.38 | 0.204 | -0.095 | -0.561 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review